Yep, yet another I am sat on where the science works, but it will take a while for the market to be convinced. Its crazy the crap the market buys into with absurd valuations on future earnings, but they cannot see the likely returns on these revolutionary areas of bio-tech. Australia has very little coverage by decent analysts in bio-tech. This is a lot to do with the depressed pricing, but a great valuation opportunity for those of us who have the patience.
Ann: Half Yearly Report and Accounts, page-21
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |